Prescription Drug Information: Loteprednol Etabonate (Page 2 of 2)
ADVERSE REACTIONS
Reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.
Ocular adverse reactions occurring in 5% to 15% of patients treated with loteprednol etabonate ophthalmic suspension (0.2% to 0.5%) in clinical studies included abnormal vision/blurring, burning on instillation, chemosis, discharge, dry eyes, epiphora, foreign body sensation, itching, injection, and photophobia. Other ocular adverse reactions occurring in less than 5% of patients include conjunctivitis, corneal abnormalities, eyelid erythema, keratoconjunctivitis, ocular irritation/pain/discomfort, papillae, and uveitis. Some of these events were similar to the underlying ocular disease being studied.
Non-ocular adverse reactions occurred in less than 15% of patients. These include headache, rhinitis and pharyngitis.
In controlled, randomized studies of individuals treated for 28 days or longer with loteprednol etabonate, the incidence of significant elevation of intraocular pressure (≥10 mmHg) was 2% (15/901) among patients receiving loteprednol etabonate, 7% (11/164) among patients receiving 1% prednisolone acetate and 0.5% (3/583) among patients receiving placebo.
To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-800-818-4555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
DOSAGE AND ADMINISTRATION
SHAKE VIGOROUSLY BEFORE USING.
Steroid Responsive Disease Treatment: Apply one to two drops of loteprednol etabonate ophthalmic suspension into the conjunctival sac of the affected eye(s) four times daily. During the initial treatment within the first week, the dosing may be increased, up to 1 drop every hour, if necessary. Care should be taken not to discontinue therapy prematurely. If signs and symptoms fail to improve after two days, the patient should be re-evaluated (see PRECAUTIONS).
Post-Operative Inflammation: Apply one to two drops of loteprednol etabonate ophthalmic suspension into the conjunctival sac of the operated eye(s) four times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the post-operative period.
HOW SUPPLIED
Loteprednol etabonate ophthalmic suspension is supplied in a white opaque LDPE plastic dropper bottle with LDPE white opaque plug and HDPE pilfer-proof pink cap as follows:
5 mL (NDC 62756-232-90)
10 mL (NDC 62756-232-55)
15 mL (NDC 62756-232-56)
Storage: Store upright between 20°C-25°C (68°-77°F). DO NOT FREEZE.
KEEP OUT OF REACH OF CHILDREN.
Rx only
Sun Pharmaceutical Medicare Ltd.
Baska Ujeti Road, Ujeti,
Halol-389350, Gujarat, India.
Distributed by:
Sun Pharmaceutical Industries, Inc.
Cranbury, NJ 08512
Version Date:
ISS. 08/2020
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL-Carton
NDC 62756-232-90
Loteprednol Etabonate Ophthalmic Suspension 0.5%
For Ophthalmic Use Only
Rx only
Sterile
5 mL SUN PHARMA
spl-loteprednol-carton
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL-Label
NDC 62756-232-90
Loteprednol Etabonate Ophthalmic Suspension 0.5%
For Ophthalmic Use Only5 mL
LOTEPREDNOL ETABONATE loteprednol etabonate suspension/ drops | |||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||
|
Labeler — Sun Pharmaceutical Industries, Inc. (146974886) |
Establishment | |||
Name | Address | ID/FEI | Operations |
Sun Pharmaceutical Medicare Limited | 725420835 | ANALYSIS (62756-232), MANUFACTURE (62756-232) |
Revised: 05/2021 Sun Pharmaceutical Industries, Inc.
RxDrugLabels.com provides trustworthy package insert and label information about marketed prescription drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by RxDrugLabels.com. Every individual prescription drug label and package insert entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.
https://rxdruglabels.com/lib/rx/rx-meds/loteprednol-etabonate-4/page/2/